

MAY

Date	Headline and Source	Link	Summary
1 st May	-	-	-
2 nd May	Sanofi launches its antidiabetic drug in India- Know cost and other key details The Financial Express, May 02, 2024	Sanofi launches its antidiabetic drug in India- Know cost and other key details	Sanofi India Limited on Wednesday announced that it has launched its new diabetes drug Soliqua in India. The launch comes after receiving the marketing authorization from the Central Drugs Standard Control Organization (CDSCO) last year.
3 rd May	Bayer Pharmaceuticals, Zydus Lifesciences successfully conclude JV Bayer Zydus Pharma Private Limited ET Health World, May 03, 2024	Bayer Pharmaceuticals, Zydus Lifesciences successfully conclude JV Bayer Zydus Pharma Private Limited	Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited announced the successful conclusion of their joint venture (JV) Bayer Zydus Pharma Private Limited (BZPPL). The 50:50 joint venture was established on January 28, 2011, for the sales and marketing of pharmaceutical products in India. Bayer is now securing full ownership of the entity, as per pre-agreed JV terms.
3 rd May	Sanofi India Reports 40% Rise In Net Profit At Rs 116.3 Crore Business World, May 03, 2024	Sanofi India Reports 40% Rise In Net Profit At Rs 116.3 Crore	Drug firm Sanofi India reported 40.28 per cent rise in net profit at Rs 116.3 crore for the third quarter ended September 30, 2017. The company, which follows January-December as the financial year, had posted a net profit of Rs 82.9 crore for the July September period last year.
3 rd May	Sanofi's diabetes drug- Soliqua® now available in India The Echo of India, May 03, 2024	Sanofi's diabetes drug- Soliqua® now available in India	Sanofi India Limited has launched its' new diabetes drug Soliqua® after having received the marketing authorization from the Central Drugs Standard Control Organization (CDSCO) earlier last year. Soliqua® is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.

3 rd May	Drugs Pricing Reforms in India: Centre Expands Industry Participation India CSR, May 03, 2024	Drugs Pricing Reforms in India: Centre Expands Industry Participation	In a significant move aimed at reforming the pricing of drugs and medical devices, the Department of Pharmaceuticals (DoP) in New Delhi has issued an order to expand its committee by including a broader range of industry representatives. (OPPI)
4 th May	AbbVie India and Sights avers India collaborate to raise awareness on Glaucoma Media brief, May 04, 2024	AbbVie India and Sights avers India collaborate to raise awareness on Glaucoma	Sights avers India, a development organisation working to eliminate avoidable blindness and promote equality of opportunity for people with disability, has collaborated with AbbVie Therapeutics India Pvt Limited to spearhead a joint campaign to enhance glaucoma awareness. This often overlooked yet widespread eye ailment impacts millions across India, necessitating urgent attention and education.
5 th May	-	-	-
6 th May	-	-	-
7 th May	-	-	-
8 th May	Emicizumab brings hope to Haemophilia A patients, accessibility remains a challenge ET Health World, May 08, 2024	Emicizumab brings hope to Haemophilia A patients, accessibility remains a challenge	V Simpson Emmanuel, MD & CEO, Roche Pharma India, said, Hemlibra (Emicizumab) is the world's first bispecific monoclonal antibody (Factor VIII Function-Mimetic) and the only treatment for Haemophilia A that can be administered subcutaneously across all age groups. Hemlibra enjoys an inimitable and proven safety profile studied in the largest and broadest trial programme spanning over eight years.
9 th May	New oral diabetes + obesity drug's India sales surge 100% The Economic Times, May 09, 2024	New oral diabetes + obesity drug's India sales surge 100%	Novo Nordisk's oral semaglutide tablet, branded Rybelsus, is gaining popularity in India though doctors have cautioned against indiscriminate use of the drug approved for treating diabetes and also for weight reduction. Sales of the drug have more than doubled in the past year to 363 crore in April

			from 147 crore a year earlier, showed data from market researcher Pharmarack Touted as a game changer for treating Type 2 diabetes , Rybelsus was launched in an oral form in India in 2022.
10 th May	New oral diabetes and obesity drug sale doubles in India amid demand surge Business Standard, May 10, 2024	New oral diabetes and obesity drug sale doubles in India amid demand surge	Novo Nordisk’s oral semaglutide tablet, known as Rybelsus, approved for treating diabetes and weight reduction, is surging in popularity in India, The Economic Times reported. According to data from market researcher Pharmarack, sales of Rybelsus have more than doubled in the past year, reaching Rs 363 crore in April as compared to Rs 147 crore a year earlier.
10 th May	AstraZeneca and Vaayu Chest & Sleep Center enhance respiratory care for severe asthma patients in Bengaluru BioSpectrum India, May 10, 2024	AstraZeneca and Vaayu Chest & Sleep Center enhance respiratory care for severe asthma patients in Bengaluru	AstraZeneca Pharma India has partnered with Vaayu Chest & Sleep Center to elevate the standard of respiratory care for severe asthma patients in Bengaluru. Severe asthma poses a significant challenge as a prevalent noncommunicable disease in India, contributing to premature morbidity and mortality. Recent data indicates that approximately 22 lakhs of individuals in Karnataka are grappling with asthma, placing the state seventh in terms of asthmatic population in India.
11 th May	Novartis India announces dividend of 25 per share, net profit slides 41% in Q4 CNBC TV18, May 11, 2024	Novartis India announces dividend of 25 per share, net profit slides 41% in Q4	Drug firm Novartis India Ltd on Friday reported a 41.6% yearonyear (YoY) decline in net profit at 14.6 crore for the fourth quarter that ended March 31, 2024. In the corresponding quarter last fiscal, Novartis India posted a net profit of 25 crore, the company said in a regulatory filing. The company s revenue from operations increased 6.7% to 81.2 crore against 76.1 crore in the corresponding period of the preceding fiscal.

11 th May	"Open to market Eli Lilly's weight loss drugs in India: Cipla CEO Money Control, May 11, 2024"	Open to market Eli Lilly's weight loss drugs in India: Cipla CEO	Indian pharma major Cipla said that it is open to the possibility of marketing Eli Lilly's weight loss drugs in India. We currently have a very nice working relation with Eli Lilly for the insulin range. So we are always open Umang Vohra, CEO, Cipla.
12 th May	"Novartis India Limited recommends final dividend of Rs. 25 EquityBulls, May 12, 2024"	Novartis India Limited recommends final dividend of Rs. 25	The Board of directors of Novartis India Limited has recommended final dividend of Rs. 25 per equity share (of the face value of Rs. 5 each) for the financial year ended March 31, 2024, subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting (AGM).
12 th May	"Cipla open to collaborate with Eli Lilly to market its obesity drugs in India: CEO Medical Dialogues, May 12, 2024"	Cipla open to collaborate with Eli Lilly to market its obesity drugs in India: CEO	The CEO of Cipla on Friday expressed openness to collaborate with U.S. pharmaceutical company Eli Lilly for the marketing of their highly successful obesity treatment medications in India. Absolutely and always open...we value our partnership with Lilly tremendously and I think the two companies are culturally aligned, Cipla's Global CEO Umang Vohra said in response to a Reuters query.
13 th May	-	-	-
14 th May	"Merck halts skin cancer combination therapy testing in late-stage study The Financial Express, May 14, 2024"	Merck halts skin cancer combination therapy testing in late-stage study	Merck on Monday announced that it has discontinued testing a combination of an experimental antibody-based drug and its blockbuster immunotherapy, Keytruda. According to the company's statement, it has been done for some patients with the most severe form of skin cancer in a late-stage study.
15 th May	"Infection Prevention & Control: P.D Hinduja hospital digitises it's AMC and IPC programs in partner with Ibhar technologies	Infection Prevention & Control: P.D Hinduja hospital digitises it's AMC and IPC programs in partner with Ibhar technologies	The transformation will use Artificial Intelligence (AI) and Machine Learning (ML) enhancing patient safety and elevate clinical outcomes and has been implemented with support from

	ET Health World, May 15, 2024"		Pfizer and Association of Healthcare Providers India (AHPI). Commenting on the partnership, Joy Chakraborty, COO, P. D. Hinduja Hospital and Medical Research Centre, said, P. D. Hinduja hospital has been at the forefront of providing quality healthcare to its patients.
15 th May	"AstraZeneca Pharma India, Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru Medical Dialogues, May 15, 2024"	AstraZeneca Pharma India, Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru	AstraZeneca Pharma India Ltd., a science-led biopharmaceutical company, has partnered with Vaayu Chest & Sleep Center to elevate the standard of respiratory care for severe asthma patients in Bengaluru.
16 th May	"India approves new treatment for severe skin disease India Today, May 16, 2024"	India approves new treatment for severe skin disease	The Central Drugs Standard Control Organisation (CDSCO) in India has given the green light to Boehringer Ingelheim's SPEVIGO (Spesolimab) injection, to help in the treatment of adults suffering from Generalised Pustular Psoriasis (GPP) flares. Generalised Pustular Psoriasis (GPP) is a rare and unpredictable systemic disease with prominent skin symptoms, distinct from plaque psoriasis.
16 th May	Boehringer Ingelheim gets CDSCO nod for drug to treat GPP ET Health World, May 16, 2024	Boehringer Ingelheim gets CDSCO nod for drug to treat GPP	Drug firm Boehringer Ingelheim on Wednesday said the domestic drug regulator has approved a medication Generalised Pustular Psoriasis (GPP) flares in adults. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Spevigo (Spesolimab) injection, a first-in-class treatment for GPP flares in adults, Boehringer Ingelheim said in a statement.
16 th May	GSK's Shingrix vaccine can prevent shingles for over a decade: Study Business Standard, May 16, 2024	GSK's Shingrix vaccine can prevent shingles for over a decade: Study	A new study has shown that GSK's shingles vaccine, Shingrix, remains effective in preventing shingles for over a decade in adults aged 50 and over. The findings, presented at a recent medical conference, come

			from a long-term follow-up trial that tracked participants for up to 11 years after vaccination.
17 th May	Novartis to acquire nearly 12 percent stake of MorphoSys AG The Financial Express, May 17, 2024	Novartis to acquire nearly 12 percent stake of MorphoSys AG	Novartis on Thursday announced the result of its voluntary public takeover offer for the shares of MorphoSys. According to the company's statement, as of the expiry of the acceptance period at 24:00 hours CEST on 13 May 2024, the Offer has been accepted by approximately 79.6 percent of the total share capital of MorphoSys, including purchases by Novartis BidCo AG outside the Offer for approximately 11.6 percent of the share capital.
18 th May	GSK Pharma Q4 results: Profit rises 45% on growth in NLEM drugs, vaccines Business Standard, May 18, 2024	GSK Pharma Q4 results: Profit rises 45% on growth in NLEM drugs, vaccines	GlaxoSmithKline (GSK) Pharmaceuticals posted a 45.7 per cent growth in consolidated net profit for Q4FY24 to Rs 194.48 crore, while its revenue from operations went up 18 per cent to Rs 929.8 crore. The board has recommended a dividend of Rs 32 per equity share on face value of Rs 10 each for the year ended 31 March 2024, subject to approval of members at the 99th Annual General Meeting
18 th May	Sanofi India Ltd spurts 2.57%, up for third straight session Business Standard, May 18, 2024	Sanofi India Ltd spurts 2.57%, up for third straight session	Sanofi India Ltd is quoting at Rs 8796.7, up 2.57% on the day as on 12:49 IST on the NSE. The stock is up 37.56% in last one year as compared to a 23.95% gain in NIFTY and a 54.96% gain in the Nifty Pharma index. Sanofi India Ltd rose for a third straight session today.
19 th May	-	-	-
20 th May	GlaxoSmithKline Consolidated March 2024 Net Sales at Rs 929.80 crore, up 18.08% YoY Money Control, May 20, 2024	GlaxoSmithKline Consolidated March 2024 Net Sales at Rs 929.80 crore, up 18.08% YoY	Net Sales at Rs 929.80 crore in March 2024 up 18.08% from Rs. 787.45 crore in March 2023. Quarterly Net Profit at Rs. 194.48 crore in March 2024 up 45.75% from Rs. 133.43 crore in March 2023. EBITDA stands at Rs. 287.09

			crore in March 2024 up 45.44% from Rs. 197.40 crore in March 2023.
21 st May	"The growing promise of cancer vaccines The Print, May 21, 2024"	The growing promise of cancer vaccines	These vaccines, jointly developed by pharma giants Moderna and Merck, have been shown in trials conducted so far to be significantly more effective in combination with immunotherapy than immunotherapy alone in preventing both the relapse of melanoma a type of skin cancer and non-small cell lung cancer after the tumours had been surgically removed.
22 nd May	"CDSCO Panel grants Novartis Protocol Amendment Proposal to study Remibrutinib in Chronic Spontaneous Urticaria Medical Dialogues, May 22, 2024"	CDSCO Panel grants Novartis Protocol Amendment Proposal to study Remibrutinib in Chronic Spontaneous Urticaria	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by the drug major Novartis for an extension study of long-term efficacy, safety, and tolerability of Remibrutinib in chronic spontaneous urticaria patients who completed preceding studies with remibrutinib.
23 rd May	Pharma Marketing Practice: Is It Necessary In The Indian Market ET Health World, May 23, 2024	Pharma Marketing Practice: Is It Necessary In The Indian Market	These guidelines include restrictions on promotional activities and requirements for disclosing financial relationships. Additionally, industry associations like the Organisation of Pharmaceutical Producers of India (OPPI) have adopted codes of conduct aimed at promoting ethical marketing practices and transparency.
24 th May	-	-	-
25 th May	-	-	-
26 th May	"Johnson and Johnson Gets CDSCO Panel Nod For Additional Indication of Daratumumab to Treat Light chain AL amyloidosis Medical Dialogues, May 26, 2024"	Johnson and Johnson Gets CDSCO Panel Nod For Additional Indication of Daratumumab to Treat Light chain AL amyloidosis	Granting local clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved Johnson and Johnson's anticancer drug Daratumumab solution for Injection

			1800 mg (120 mg/ml) for an additional indication for the treatment of Light chain (AL) amyloidosis in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic AL amyloidosis.
27 th May	-	-	-
28 th May	"AstraZeneca Pharma India Gets CDSCO Panel Nod To Import, Market Eculizumab for Atypical hemolytic uremic syndrome Medical Dialogues, May 28, 2024"	AstraZeneca Pharma India Gets CDSCO Panel Nod To Import, Market Eculizumab for Atypical hemolytic uremic syndrome	The drug major AstraZeneca Pharma India has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to import and market the drug Eculizumab concentrate for solution for infusion 300 mg for indication of Atypical hemolytic uremic syndrome (aHUS).
29 th May	"Special Address: Anil Matai, Director General, OPPI Express Pharma, May 29, 2024"	Special Address: Anil Matai, Director General, OPPI	Supply chain plays a critical role in converting PM Modi's clarion call of Viksit Bharat into reality. As environmental concerns escalate and consumer preferences evolve, pharma and med devices supply chains must make sustainability an imperative.
29 th May	Pharma Marketing Practice: Is It Necessary In The Indian Market Business News This Week, May 29, 2024	Pharma Marketing Practice: Is It Necessary In The Indian Market	These guidelines include restrictions on promotional activities and requirements for disclosing financial relationships. Additionally, industry associations like the Organisation of Pharmaceutical Producers of India (OPPI) have adopted codes of conduct aimed at promoting ethical marketing practices and transparency.
29 th May	AstraZeneca Pharma Q4 PAT soars 129% YoY to Rs 39 cr Business Standard, May 29, 2024	AstraZeneca Pharma Q4 PAT soars 129% YoY to Rs 39 cr	Dr. Sanjeev Panchal, country president and managing director, AstraZeneca India, commented, AstraZeneca India products sales for first time cross Rs 1,000 crore mark, delivering total revenue of

			almost Rs Rs 1,300 crore with growth of 29% this year.
30 th May	Pharma heads to self-declare on ethical code compliance, a first under the updated UCPMP The Hindu Business Line, May 30, 2024	Pharma heads to self-declare on ethical code compliance, a first under the updated UCPMP	Anil Matai, Director General with the Organisation of Pharmaceutical Producers of India (OPPI), a platform of largely foreign drugmakers, said companies were already primed since the code was issued earlier this year, and the self-declarations would go up on the association's website.
30 th May	Novartis Gets CDSCO Panel Nod to Study Iptacopan in Atypical Hemolytic Uremic Syndrome Medical Dialogues, May 30, 2024	Novartis Gets CDSCO Panel Nod to Study Iptacopan in Atypical Hemolytic Uremic Syndrome	The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III b clinical study to evaluate the long-term safety, tolerability and efficacy of Iptacopan in aHUS (atypical hemolytic uremic syndrome).
30 th May	Hyderabad: Pfizer, Yashoda Hospitals Inaugurate Centre of Excellence for Adult Vaccination Deccan Chronicle, May 30, 2024	Hyderabad: Pfizer, Yashoda Hospitals Inaugurate Centre of Excellence for Adult Vaccination	Pfizer India and Yashoda Hospitals have collaborated to inaugurate a new dedicated Centre of Excellence (CoE) for adult vaccination in Yashoda Hospitals Hitec City, Hyderabad. With a vision of enhancing patient care, the CoE was designed to ensure holistic coverage of adult vaccination across the community.
30 th May	AstraZeneca Pharma India Q4 Results Live : profit rise by 128.61% YOY Live Mint, May 30, 2024	AstraZeneca Pharma India Q4 Results Live : profit rise by 128.61% YOY	AstraZeneca Pharma India declared their Q4 results on 27 May, 2024. The topline increased by 34.6% & the profit increased by 128.61% YoY. As compared to the previous quarter the revenue grew by 25.31% and the profit increased by 149.84%.
31 st May	Pharmaceutical companies prepare to comply with ethical marketing code Business Standard, May 31, 2024	Pharmaceutical companies prepare to comply with ethical marketing code	Anil Matai, director-general of the Organisation of Pharmaceutical Producers of India, which represents multinational pharma companies working in India, said that pharma companies had been diligently preparing to align with this

			ethical code since its issuance in March this year.
31 st May	We are moving into newer disease areas; Xenpozyme will be launched in India soon: Anil Raina, GM, Sanofi Specialty Care, India The Financial Express, May 31, 2024	We are moving into newer disease areas; Xenpozyme will be launched in India soon: Anil Raina, GM, Sanofi Specialty Care, India	To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. Diagnosing and treating rare diseases is extremely complex. However, various pharmaceutical companies like Sanofi have played a crucial role in the development of the drugs for rare diseases.
31 st May	Pfizer and Yashoda Hospitals Hitec City Hyderabad, Inaugurate Centre of Excellence for Adult Vaccination The Hans India, May 31, 2024	Pfizer and Yashoda Hospitals Hitec City Hyderabad, Inaugurate Centre of Excellence for Adult Vaccination	Pfizer India and Yashoda Hospitals have collaborated to inaugurate a new dedicated Centre of Excellence (CoE) for adult vaccination in Yashoda Hospitals Hitec City, Hyderabad. With a vision of enhancing patient care, the CoE was designed to ensure holistic coverage of adult vaccination across the community.
